A new Lyme disease vaccine – bravery to be rewarded
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Lyme Borreliosis (Lyme Disease) vaccines.
New Anti-RSV monoclonal antibodies - for the many? or still for the few?
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand new commercial assessment of anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies. If used in all, rather than selected infants, this product concept promises a new alternative to vaccines for tackling this dangerous pathogen. But does more…
RSV vaccines - risk, competition and a big prize, eventually
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines, releases a brand new commercial assessment of Respiratory Syncytial Virus (RSV) vaccines. The field is one of the most active in the vaccine industry with many competitors investigating numerous approaches. But will the first mover reap the biggest reward?
MERS-CoV, Lassa and Nipah - analysing the demand case for new vaccines
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines, releases three detailed demand analyses for MERS-CoV, Lassa virus and Nipah virus vaccines.
mRNA vaccines for infectious diseases - gathering momentum...
This month VacZine Analytics releases an updated analysis focused on the high-profile emerging field of mRNA vaccines. This technology promises much, and analysis shows the pipeline is gathering momentum.
A Lassa fever vaccine - follow the footsteps of Ebola
This month VacZine Analytics releases MarketVIEW: Lassa fever vaccines. Lassa Fever is a priority target for international stakeholders, with significant sums of money already donated to develop a preventative vaccine. After apparent success with Ebola vaccine development, should the wider industry be interested in this new business model?
The potential of a Chikungunya vaccine - unpredictably attractive
This month VacZine Analytics releases MarketVIEW: Chikungunya vaccines. As more countries report local or autochthonous transmission of this problematic virus, and two vaccines receive priority designation, VacZine Analytics investigates commercial potential.
Influenza vaccines and national policy - the good, the bad and the ugly...
This month VacZine Analytics releases its newly updated value/volume forecast for the global market for seasonal influenza vaccines. The influenza vaccine recommendations for 35 countries (13 Western and 21 Emerging/ROW) have been assessed, with some interesting findings.
Human Papilloma Virus (HPV) therapeutic vaccines - close to reality?
This month VacZine Analytics releases a new commercial analysis focused on Human Papilloma Virus (HPV) therapeutic vaccines. With efficacy signals observed in cervical neoplasias and established cancers, this approach may reinvigorate the concept of a "cancer" vaccine.
mRNA vaccines - disruption or distraction?
This month VacZine Analytics releases a brand new analysis focused on the high profile emerging field of mRNA vaccines. This technology promises much, but what is real and what is hype?
VacZine Analytics releases updated dengue (endemic) and dengue (travelers) vaccine forecasts
This month VacZine Analytics has updated both its dengue (endemic) and dengue (travelers) vaccine forecasts giving its latest view on this controversial vaccine market.
VacZine Analytics releases MarketVIEW: Opioid use disorder vaccines
A brand-new research study: "MarketVIEW: Opioid use disorder (OUD) vaccines report” has recently been added to VacZine Analytics portfolio offering.
VacZine Analytics releases MarketVIEW: Chagas disease vaccines
What is the most financially viable vaccine strategy for Chagas disease vaccines? Today UK based vaccine strategic consultancy releases a brand new market analysis MarketVIEW: Chagas disease vaccines.
VacZine Analytics releases MarketVIEW: inactivated polio virus vaccines
Who will benefit from the boom in inactivated polio virus vaccines? Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for inactivated polio virus vaccines.
VacZine Analytics releases MarketVIEW: Cocaine dependence vaccines
Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for cocaine dependence vaccines.
VacZine Analytics releases MarketVIEW: Ross River Virus vaccines
Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for Ross River Virus vaccines.
VacZine Analytics releases MarketVIEW: diabetes vaccines
Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for diabetes vaccines.
VacZine Analytics releases: MarketVIEW - typhoid travel vaccines
UK-based strategic research consultancy VacZine Analytics has released a new commercial market forecast for Typhoid travel vaccines.